X-linked Adrenoleukodystrophy Clinical Trial
Official title:
Exercise Study of Function and Pathology for Women With X-ALD
NCT number | NCT01594853 |
Other study ID # | NA_00045673 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2012 |
Est. completion date | October 2014 |
Verified date | December 2017 |
Source | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose is to see how X-linked adrenoleukodystrophy (X-ALD) is associated with strength and sensation using MRI, in women with X-ALD. The investigators will also see whether exercise can improve these symptoms for women with X-ALD.
Status | Completed |
Enrollment | 31 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 21 Years to 70 Years |
Eligibility |
Inclusion Criteria: - confirmed diagnosis, X-ALD heterozygote carrier - no medical contraindication to participating in a strength training program - able to follow complex directions as determined by a score of =1 on a subset of questions taken from the NIH Stroke scale (Brott et al. 1989) - hip flexion strength: 6.6-15.8kg - hip extension strength: up to 18.3 kg - normal passive range of motion at hips/knees/ankles - able to walk =50m Exclusion Criteria: - Evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease - congestive heart failure - cancer - orthopedic conditions - severe pain that precludes study participation - seizures - pregnancy - other medical condition that precludes participation in an exercise program, e.g., unstable angina, uncontrolled diabetes, uncontrolled hypertension Healthy controls have the same age and exclusion criteria as women with AMN except that they will not be carriers for X-ALD. They must have normal neurological function. |
Country | Name | City | State |
---|---|---|---|
United States | Motion Analysis Lab | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | European Leukodystrophy Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Maximal Voluntary Contraction of the Hip Flexors From Baseline to End of Training and to Post-training | Here, we will assess whether the degree of a person's white matter integrity (i.e. for tracts of interest as measured from MRI) predicts their ability to benefit from exercise. Our prediction is that those individuals with preserved white matter integrity will show the greatest improvement in hip flexor strength. | Participants are assessed at baseline (visit 1, enrollment), end of training (visit 2, week 12) and post-training (visit 3, week 18). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05911919 -
Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy
|
||
Recruiting |
NCT03727555 -
Lentiviral Gene Therapy for X-ALD
|
N/A | |
Completed |
NCT02595489 -
A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
|
Phase 1 | |
Completed |
NCT04687007 -
SMART-ALD - A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD)
|
N/A | |
Completed |
NCT01165060 -
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
|
N/A | |
Recruiting |
NCT05939232 -
Registry of X-linked Adrenoleukodystrophy
|
||
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Completed |
NCT03864523 -
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy
|
Phase 2 | |
Recruiting |
NCT06178120 -
Disease Progression in Women With X-linked Adrenoleukodystrophy
|
||
Recruiting |
NCT03278899 -
A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
|
||
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Recruiting |
NCT04675749 -
Quality of Life in Women With X-linked Adrenoleukodystrophy
|
||
Withdrawn |
NCT03196765 -
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01787578 -
Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
|
Phase 1 | |
No longer available |
NCT02233257 -
Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy
|
N/A |